ReviewCells2020
Nutraceuticals and Exercise against Muscle Wasting during Cancer Cachexia.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 40 citations in OpenAlex.
- Cancer-associated adipocytes: metabolic reprogramming, crosstalk and therapeutic implications in tumor progression.Signal transduction and targeted therapy · 2026Review
- Identification of Kaempferol for Skeletal Muscle Wasting in Cancer Cachexia Through Bibliometric Analysis and Network Pharmacology: Metabolomic and Experimental Evaluation.Biological procedures online · 2026Article
- MyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.Journal of cachexia, sarcopenia and muscle · 2026Article
- Integrating polyphenols and exercise in cancer prevention, treatment, and rehabilitation: cellular and molecular mechanisms linking the injury-recovery-musculoskeletal resilience axis.Frontiers in oncology · 2026Review
- Cisplatin-Induced Skeletal Muscle Atrophy: Biomolecular Mechanisms and the Protective Role of Exercise-Induced Myokines.Biomolecules · 2025Review
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Frontiers in immunology · 2025Review
- The emerging role of exercise preconditioning in preventing skeletal muscle atrophy.Frontiers in physiology · 2025Review
- Reduced myotube diameter induced by combined inhibition of transforming growth factor-β type I receptors Acvr1b and Tgfbr1 is associated with enhanced β1-syntrophin expression.Journal of cellular physiology · 2024Article
- Exercise and nutrition benefit skeletal muscle: From influence factor and intervention strategy to molecular mechanism.Sports medicine and health science · 2024Review
- Chemical Characterization and In Vitro Evaluation of Glucans from Fermentation-Produced Nutraceutical Bionutri-AR1Pharmaceutics · 2024Article
- Influence of Amino Acids and Exercise on Muscle Protein Turnover, Particularly in Cancer Cachexia.Cancers · 2024Review
- Treatment of Cachexia in Gastric Cancer: Exploring the Use of Anti-Inflammatory Natural Products and Their Derivatives.Nutrients · 2024Review
- Molecular Mechanisms of Cachexia: A Review.Cells · 2024Review
- Unlocking Prognostic Genes and Multi-Targeted Therapeutic Bioactives from Herbal Medicines to Combat Cancer-Associated Cachexia: A Transcriptomics and Network Pharmacology Approach.International journal of molecular sciences · 2023Article
- A Review of Nutraceuticals in Cancer Cachexia.Cancers · 2023Review
- Protein therapy of skeletal muscle atrophy and mechanism by angiogenic factor AGGF1.Journal of cachexia, sarcopenia and muscle · 2023Article
- Introduction to the Special Issue "Skeletal Muscle Atrophy: Mechanisms at a Cellular Level".Cells · 2023Article
- Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting.Antioxidants & redox signaling · 2023Review
- Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cancer cachexia (CC) is a debilitating multifactorial syndrome, involving progressive deterioration and functional impairment of skeletal muscles. It affects about 80% of patients with advanced cancer and causes premature death. No causal therapy is available against CC. In the last few decades, our understanding of the mechanisms contributing to muscle wasting during cancer has markedly increased. Both inflammation and oxidative stress (OS) alter anabolic and catabolic signaling pathways mostly culminating with muscle depletion. Several preclinical studies have emphasized the beneficial roles of several classes of nutraceuticals and modes of physical exercise, but their efficacy in CC patients remains scant. The route of nutraceutical administration is critical to increase its bioavailability and achieve the desired anti-cachexia effects. Accumulating evidence suggests that a single therapy may not be enough, and a bimodal intervention (nutraceuticals plus exercise) may be a more effective treatment for CC. This review focuses on the current state of the field on the role of inflammation and OS in the pathogenesis of muscle atrophy during CC, and how nutraceuticals and physical activity may act synergistically to limit muscle wasting and dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.